Potency of clinical group B streptococcal conjugate vaccines
- 22 February 2001
- Vol. 19 (15-16) , 2118-2126
- https://doi.org/10.1016/s0264-410x(00)00437-0
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Use of Capsular Polysaccharide–Tetanus Toxoid Conjugate Vaccine for Type II Group BStreptococcusin Healthy WomenThe Journal of Infectious Diseases, 2000
- Group B Streptococcal Disease in the Era of Intrapartum Antibiotic ProphylaxisNew England Journal of Medicine, 2000
- Synthesis and Preclinical Evaluation of Glycoconjugate Vaccines against Group BStreptococcusTypes VI and VIIIThe Journal of Infectious Diseases, 1999
- Safety and Immunogenicity of Capsular Polysaccharide–Tetanus Toxoid Conjugate Vaccines for Group B Streptococcal Types Ia and IbThe Journal of Infectious Diseases, 1999
- Theraputic Potential of Human Antisera to Group B Streptococcal Glycoconjugate Vaccines in Neonatal MiceThe Journal of Infectious Diseases, 1997
- Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.Journal of Clinical Investigation, 1996
- Immunogenicity and Protective Activity in Animals of a Type V Group B Streptococcal Polysaccharide-Tetanus Toxoid Conjugate VaccineThe Journal of Infectious Diseases, 1995
- Maternal immunization of mice with group B streptococcal type III polysaccharide-beta C protein conjugate elicits protective antibody to multiple serotypes.Journal of Clinical Investigation, 1994
- Neonatal Mouse Model of Group B Streptococcal InfectionThe Journal of Infectious Diseases, 1992
- Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus.Journal of Clinical Investigation, 1990